Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

Src tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We performed a CTEP-sponsored Phase II clinical trial of saracatinib in previously treated pancreas cancer patients, with a prim...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Arcaroli, John, Quackenbush, Kevin, Dasari, Arvind, Powell, Rebecca, McManus, Martine, Tan, Aik-Choon, Foster, Nathan R, Picus, Joel, Wright, John, Nallapareddy, Sujatha, Erlichman, Charles, Hidalgo, Manuel, Messersmith, Wells A
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2012
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3544442/
https://ncbi.nlm.nih.gov/pubmed/23342270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.27
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars